TheranosticTrials.org
Clarity Pharmaceuticals

Clinical Trial · NCT00100256

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Overview

The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.

Sponsor

Clarity Pharmaceuticals

Phase

Phase 1/2

Contacts

For trial location information Andarix (CONTACT)

info@andarix.com

617-957-9858

Trials Andarix Clinical Trials Contact (CONTACT)

info@andarix.com

Andarix Study Director (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT00100256

Drug / Compound

P2045

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides

P2045

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides

Eligibility

Inclusion

  • Has measurable tumor (at least 1 cm unidimensionally) in a previously non-irradiated area or, if in previously irradiated area, a substantial increase in size of tumor, based on CT scan within 8 weeks prior to enrollment; tumor in previously irradiated area only if it has increased by 50% or more from previous minimal diameter AND it is more than 8 weeks from the radiation.
  • Has histologically or cytologically documented Non-Small-Cell Lung Cancer (NSCLC) or Small-Cell Lung Cancer (SCLC) and has advanced or recurrent IIIb or IV NSCLC (adenocarcinoma, squamous cell carcinoma, large cell, mixed or not otherwise specified) or disseminated or recurrent SCLC or any lung cancer which has local recurrence.
  • Has documentation of progressive disease following prior chemotherapy or who refused to receive standard chemotherapy.

Exclusion

Exclusion criteria not yet provided.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…